Triple-negative breast cancer (TNBC) is known to have a poor prognosis and limited treatment options, namely chemotherapy. Different molecular studies have recently classified TNBC into different subtypes opening the door to potential new-targeted treatment options. In this review, we discuss the current standard of care in the treatment of TNBC in the neoadjuvant, adjuvant and metastatic settings. In addition, we summarize the ongoing phase III clinical trials evaluating different associations between the 3 pillars of anticancer treatment: chemotherapy, targeted therapy and immunotherapy.
Titolo: | Triple-negative breast cancer: Current perspective on the evolving therapeutic landscape |
Autori: | |
Data di pubblicazione: | 2019 |
Rivista: | |
Handle: | http://hdl.handle.net/11567/975360 |
Appare nelle tipologie: | 01.01 - Articolo su rivista |
File in questo prodotto:
File | Descrizione | Tipologia | |
---|---|---|---|
Mehanna J et al_Int J Women's Health 2019.pdf | Documento in versione editoriale | Open Access Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.